Acute Brochitis by Wenzel, Richard P. & Fowler III, Alpha A.
Virginia Commonwealth University
VCU Scholars Compass
Internal Medicine Publications Dept. of Internal Medicine
2006
Acute Brochitis
Richard P. Wenzel
Virginia Commonwealth University, rwenzel@mcvh-vcu.edu
Alpha A. Fowler III
Virginia Commonwealth University, afowler@mcvh-vcu.edu
Follow this and additional works at: http://scholarscompass.vcu.edu/intmed_pubs
Part of the Medicine and Health Sciences Commons
From The New England Journal of Medicine, Wenzel, R. P. and Fowler III, A. A., Acute Bronchitis, Vol. 355, Page 2125,
Copyright © 2006 Massachusetts Medical Society. Reprinted with permission.
This Article is brought to you for free and open access by the Dept. of Internal Medicine at VCU Scholars Compass. It has been accepted for inclusion
in Internal Medicine Publications by an authorized administrator of VCU Scholars Compass. For more information, please contact
libcompass@vcu.edu.
Downloaded from
http://scholarscompass.vcu.edu/intmed_pubs/41
clinical practice
T h e  n e w  e ng l a nd  j o u r na l  o f  m e dic i n e
n engl j med 355;20 www.nejm.org november 16, 2006 2125
This Journal feature begins with a case vignette highlighting a common clinical problem. 
Evidence supporting various strategies is then presented, followed by a review of formal guidelines, 
when they exist. The article ends with the authors’ clinical recommendations. 
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A 40-year-old man with no underlying lung disease has a 7-day history of mild shortness 
of breath with exertion, as well as cough that is now productive of purulent sputum. 
He reports no paroxysms of cough and no contact with ill persons in his community. 
He does not appear to be in distress. His temperature is 37°C, his pulse 84 beats per 
minute, and his respiratory rate 17 breaths per minute. On auscultation of the lungs, 
no rales are heard; scattered wheezes are heard in the lung bases. How should he be 
evaluated and treated?
The Cl inic a l Problem
Acute bronchitis is a clinical term implying a self-limited inflammation of the large 
airways of the lung that is characterized by cough without pneumonia. The disorder 
affects approximately 5% of adults annually,1,2 with a higher incidence observed dur-
ing the winter and fall than in the summer and spring. In the United States, acute 
bronchitis is the ninth most common illness among outpatients, as reported by phy-
sicians.3
Viruses are usually considered the cause of acute bronchitis but have been isolated 
in a minority of patients.1,4 Those isolated in acute bronchitis (from the most to the 
least common in large series) include influenza A and B viruses, parainfluenza virus, 
respiratory syncytial virus, coronavirus, adenovirus, and rhinovirus. Human meta-
pneumovirus has been identified as a causative agent.5-7 A recent French study in-
volving adults who had been vaccinated against influenza showed a viral cause in 37% 
of 164 cases of acute bronchitis, of which 21% were rhinovirus.4 Thus, the yield of 
specific pathogens varies according to several factors, including the presence or ab-
sence of an epidemic, the season of the year, and the influenza vaccination status of 
the population.
Bacterial species commonly implicated in community-acquired pneumonias are 
isolated from the sputum in a minority of patients with acute bronchitis.1 However, 
the role of these species in the disease or its attendant symptoms remains unclear, 
because bronchial biopsies have not shown bacterial invasion. In some cases, atypi-
cal bacteria are important causes, including Bordetella pertussis, Chlamydophila (Chlamydia) 
pneumoniae, and Mycoplasma pneumoniae.1 Some data have suggested that B. pertussis 
may underlie 13 to 32% of cases of cough lasting 6 days or longer, although in a recent 
prospective study, B. pertussis comprised only 1% of cases of acute bronchitis.8
Pathobiology
Acute bronchitis is thought to reflect an inflammatory response to infections of the 
epithelium of the bronchi. Epithelial-cell desquamation and denuding of the airway 
to the level of the basement membrane in association with the presence of a lympho-
cytic cellular infiltrate have been demonstrated after influenza A tracheobronchitis9; 
The New England Journal of Medicine 
Downloaded from nejm.org at VIRGINIA COMMONWEALTH UNIV on January 22, 2015. For personal use only. No other uses without permission. 
 Copyright © 2006 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ng l a nd  j o u r na l  o f  m e dic i n e
n engl j med 355;20 www.nejm.org november 16, 20062126
microscopical examination has shown thickening 
of the bronchial and tracheal mucosa correspond-
ing to the inflamed areas. Such pathological 
findings are consistent with reports of proximal 
lower airway inflammation confined to the bron-
chi, as detected by positron-emission tomography 
with 18F-fluorodeoxyglucose as a tracer, in the 
setting of acute bronchitis.10
However, there are wide variations in the ana-
tomical distribution of many pathogens that cause 
acute bronchitis. In a study involving volunteers 
exposed to rhinovirus infections, for example, 
virus was detected in specimens of induced spu-
tum obtained from all the subjects, in approxi-
mately one third of bronchial biopsy specimens, 
in almost a quarter of bronchoalveolar lavage 
specimens, and in more than a third of bronchial 
brushing specimens.11 Such data indicating viral 
infection of the lower airways may help to explain 
the relationship observed between rhinovirus in-
fection (and other presumed upper respiratory 
viral infections) and exacerbation of asthma.12 
Thus, although its name suggests only large-air-
way disease, acute bronchitis may be accompanied 
by an array of symptoms, depending on the de-
gree of viral involvement of the large and small 
airways.
Natural History
During the first few days of infection, the symp-
toms of mild upper respiratory infections cannot 
be distinguished from those of acute bronchitis. 
However, with acute bronchitis, coughing persists 
for more than 5 days, and during this protracted 
period the results of pulmonary function testing 
may become abnormal. Forty percent of patients 
have significant reductions in the forced expirato-
ry volume in 1 second (i.e., a value below 80% of 
the predicted value)13 or bronchial hyperreactivity, 
as measured by bronchial provocation,14 with im-
provement during the following 5 to 6 weeks.
Cough after acute bronchitis typically persists 
for 10 to 20 days but occasionally may last for 4 or 
more weeks. In a recent report on a clinical trial 
of the efficacy of an acellular pertussis vaccine in-
volving 2781 healthy adults, the median duration 
of cough from acute bronchitis due to all causes 
was 18 days (mean, 24).8 In addition, approximate-
ly 50% of patients with acute bronchitis report 
the production of purulent sputum. In otherwise 
healthy patients, purulent sputum usually indi-
cates the presence of sloughed tracheobronchial 
epithelium and inflammatory cells, and its posi-
tive predictive value for the presence of alveolar 
disease is low (approximately 10%).15
A study of the quality of life of patients with 
upper respiratory tract infections, some of whom 
had received a diagnosis of acute bronchitis, 
showed significant decrements in seven subscales 
of the Medical Outcomes Study 36-item Short-
Form General Health Survey, including vitality and 
social functioning,16 but such decrements are pre-
sumed to be transient. Data on short- or long-term 
outcomes are limited, but one study indicated that 
within a month after the initial visit, up to 20% 
of patients had reconsulted their physicians be-
cause of persistent or recurrent symptoms.1 The 
effect of an episode of acute bronchitis on a pa-
tient’s subsequent lung health is uncertain. In one 
study, 34% of patients with acute bronchitis re-
ceived a new diagnosis of chronic bronchitis or 
asthma at 3 years of follow-up.17 In another study, 
mild bronchial asthma was diagnosed on the basis 
of spirometry or bronchial provocation in 65% of 
patients with recurrent episodes of acute bronchi-
tis.18 However, these studies lacked control groups, 
and it is unclear whether acute bronchitis led di-
rectly to the chronic condition or whether the 
chronic disorder or the propensity for its devel-
opment was present at the time of the inflamma-
tion of the large airway.
S tr ategies a nd E v idence
Diagnosis
Acute bronchitis should be differentiated from 
acute inflammation of the small airways — asth-
ma or bronchiolitis — which typically presents as 
progressive cough accompanied by wheezing, 
tachypnea, respiratory distress, and hypoxemia. 
It should also be distinguished from bronchiecta-
sis,19 a distinct phenomenon associated with per-
manent dilatation of bronchi and chronic cough. 
The diagnosis of chronic bronchitis is reserved 
for patients who have cough and sputum produc-
tion on most days of the month for at least 3 months 
of the year during 2 consecutive years.20 The acute 
exacerbation of chronic bronchitis, identified by 
the worsening air flow and symptoms in such pa-
tients, is not discussed here.
A careful history taking, including reports of 
contact with ill people, and physical examination 
may suggest a specific cause (Table 1). A common 
presentation of pertussis is cough of 2 to 3 weeks’ 
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duration in an adolescent or young adult; fever is 
less common in pertussis than in viral bronchi-
tis.18,26 However, in the absence of an epidemic, 
the positive predictive value of young age, pro-
longed cough, or the absence of fever is low for 
pertussis. During an epidemic of influenza, the 
finding of both cough and fever was reported to 
have a positive predictive value of 79% for this 
condition.27
Diagnostic Testing
At the bedside, cough in the absence of fever, tachy-
cardia, and tachypnea suggests bronchitis, rather 
than pneumonia. In fact, the presence of normal 
Table 1. Recognized Causes of Acute Bronchitis and Options for Therapy.*
Pathogen Comments† Options for Therapy 
Virus
Influenza virus Precipitous onset with fever, chills, headache, and 
cough. Myalgias are common and may be ac-
companied by myositis, myoglobinuria, and 
elevated serum levels of muscle enzymes.
Oseltamivir (Tamiflu, Roche) for 5 days at a dose of 
75 mg twice daily21 or zanamivir (Relenza, 
GlaxoSmithKline) for 5 days at a dose of 
two puffs (5 mg/puff) twice daily, for a 
 total daily dose of 20 mg21
Parainfluenzavirus Epidemics may occur in autumn. Outbreaks may 
occur in nursing homes. Croup in a child at 
home suggests the presence of the organism.
None available
Respiratory syncytial virus Family history is important: approximately 45% 
of family members exposed to an infant (≤1 yr 
of age) with bronchiolitis become infected.22 
Outbreaks occur in winter or spring. Twenty 
percent of adults have ear pain.23
None available
Coronavirus Pathogen can cause severe respiratory symptoms 
in elderly patients. Epidemics of strain 0C43 
with high attack rates have been reported 
among military recruits.24
None available
Adenovirus Infection is clinically similar to influenza, with 
abrupt onset with fever.
None available
Rhinovirus Fever is uncommon, and infection is generally mild. None available
Atypical bacteria
Bordetella pertussis Incubation period is 1–3 wk. Primarily affects ado-
lescents and young adults. In some series, 10 to 
20% of patients have cough with a duration of 
>2 wk.13 Whooping occurs in a minority of pa-
tients.19 Fever is uncommon. A marked leukocy-
tosis with lymphocytic predominance can occur.
Macrolides as first-line therapy25:
Azithromycin (Zithromax, Pfizer) for 5 days at 
a dose of 500 mg on day 1 and 250 mg on 
days 2–5 or
Erythromycin (Ery-Tab, Abbott) for 14 days at 
a dose of 500 mg 4 times daily or
Clarithromycin (Biaxin, Abbott) for 7 days at 
a dose of 500 mg twice daily
Second-line therapy25:
Trimethoprim–sulfamethoxazole (Bactrim, 
Roche) for 14 days at a dose of 1600 mg 
once daily or 800 mg twice daily
Mycoplasma pneumoniae Incubation period is 2–3 wk. Gradual onset (2–3 
days) distinguishes this infection from influen-
za. Clusters occur among military recruits and 
students in boarding schools.
Azithromycin for 5 days at a dose of 500 mg on 
day 1 and 250 mg on days 2–5 or doxycy-
cline (Vibramycin, Pfizer) for 5 days at a 
dose of 100 mg twice daily or no therapy‡
Chlamydophila pneumoniae Incubation period is 3 wk. Onset of symptoms, 
which include hoarseness before cough, is grad-
ual. Clusters reported among military recruits, 
college students, and patients in nursing homes.
Azithromycin for 5 days at a dose of 500 mg on 
day 1 and 250 mg on days 2–5 or doxycy-
cline for 5 days at a dose of 100 mg twice 
daily or no therapy‡
* The cause of many cases remains uncertain. The presence or absence of a community epidemic, the time of year, the population affected, 
and influenza immunization status are important risk factors for specific pathogens. Viruses generally have an incubation period of 2 to 
7 days, whereas the three atypical bacteria have longer incubation periods. Such information may be helpful if the interval after contact with 
ill persons is known. A gradual onset of symptoms (2 to 3 days) is more characteristic of bacterial causes than of most viral causes.
† Diagnostic testing is most useful for identifying treatable causes when an infectious agent is circulating in the community and for identify-
ing a cause in an outbreak.
‡ There are no compelling data suggestive of improved outcomes of acute bronchitis as a result of treatment with antibiotic agents.
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vital signs and the absence of rales and egophony 
on chest examination minimize the likelihood of 
pneumonia to the point at which further diagnos-
tic testing is usually unnecessary.28 An exception, 
however, is cough in elderly patients; pneumonia 
in elderly patients is often characterized by an ab-
sence of distinctive signs and symptoms. Among 
patients 75 years of age or older who had commu-
nity-acquired pneumonia, only 30% had a tempera-
ture above 38°C, and only 37% had a heart rate of 
more than 100 beats per minute.29
Rapid diagnostic tests exist for several patho-
gens currently linked to acute bronchitis. However, 
not all the rapid tests are widely available, and 
their routine use is not cost-effective in an outpa-
tient setting. Rapid tests should be used primarily 
when the suspected organism is treatable, the in-
fection is known to be circulating in the commu-
nity, and the patient has suggestive symptoms or 
signs (e.g., testing for influenza during influenza 
season in patients with cough and fever) (Table 1). 
Multiplex polymerase-chain-reaction (PCR) testing 
of nasopharyngeal swabs or aspirates is being 
developed to diagnose infections resulting from 
B. pertussis, M. pneumoniae, or C. pneumoniae with 
clinically useful sensitivity and specificity, as com-
pared with culture or monoplex PCR.30
Treatment
Antimicrobial Therapy
Antimicrobial agents are not recommended in most 
cases of acute bronchitis. Systematic analyses of 
clinical trials have suggested that antibiotics may 
reduce the duration of symptoms, but at best mod-
estly. Specifically, a meta-analysis of eight trials 
involving patients with acute bronchitis suggest-
ed that symptoms were reduced by a fraction a day 
with the use of erythromycin, doxycycline, or tri-
methoprim–sulfamethoxazole. The results were 
statistically significant but clinically trivial.31 Re-
sults of a randomized, double-blind trial com-
paring a 5-day course of azithromycin in 112 pa-
tients with vitamin C in 108 patients (total dose of 
each agent, 1.5 g), published after the meta-analy-
sis had been completed, showed no difference 
between groups in the health-related quality of 
life at 7 days (the primary outcome) or in the pro-
portion of patients who returned to work, school, 
or usual activities at home on day 3 or 7.32
A Cochrane Review of nine randomized, con-
trolled trials of antibiotic agents (including three 
trials not included in the previous review31) also 
showed a significant but minor reduction in the 
duration of cough (0.6 day).33 There was a nonsig-
nificant reduction in the number of days of feel-
ing ill and a nonsignificant increase in adverse 
events attributed to antibiotics (relative risk of 
adverse events, 1.22; 95% confidence interval, 0.94 
to 1.58).
Antimicrobial therapy may be more beneficial 
when a treatable pathogen is identified than when 
a treatable pathogen is not identified. For exam-
ple, anti-influenza agents (including oseltamivir 
and zanamivir) decrease the duration of symptoms 
by approximately 1 day and result in an earlier 
return to normal activity (by 0.5 day) among pa-
tients with infections caused by susceptible virus-
es. Prompt antibiotic treatment of patients with 
pertussis is indicated to limit transmission, but 
(with the possible exception of therapy initiated 
during the first week of symptoms) there are no 
compelling data to support the prospect that 
cough will be less severe or less prolonged with 
antibiotic therapy. Similarly, although several class-
es of antibiotics have in vitro activity against 
M. pneumoniae and C. pneumoniae, it is unclear 
whether antibiotic treatment of bronchitis linked 
to these organisms influences outcomes. Table 1 
includes suggested antimicrobial therapy for 
cases in which such therapy is considered.
Other Therapy
The few randomized, placebo-controlled trials that 
have examined the effect of β2-agonists adminis-
tered orally or by aerosol for cough associated with 
acute bronchitis have involved small numbers of 
patients and have had mixed results.34-36 In these 
studies, among patients without preexisting lung 
disease, daily cough scores and the likelihood of 
persistent cough after 7 days did not differ signifi-
cantly between the active treatment and placebo 
groups. However, in one trial, a subgroup of pa-
tients with evidence of airflow limitation had sig-
nificantly lower scores for symptoms on day 2 after 
treatment with β2-agonists.34 A recent Cochrane 
Review of five trials involving 418 adults showed 
that even among patients with airflow obstruction, 
the potential benefit of β2-agonists is not well 
supported and should be balanced against the ad-
verse effects of treatment.37 In practice, a brief trial 
(7 days) of inhaled or oral corticosteroids may be 
reasonable for troublesome cough (i.e., cough per-
sisting for more than 20 days), but there are no 
clinical trial data to support this approach. Data 
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from clinical trials are also not available to support 
the use of mucolytic or antitussive agents.
A r e a s of Uncerta in t y
Distinguishing the minority of cases of acute bron-
chitis due to a treatable cause from those due to 
currently nontreatable viruses is often challeng-
ing. Recently, the measurement of serum levels of 
procalcitonin, which is typically elevated in bacte-
rial infections, has been proposed as a means of 
identifying patients in whom treatment with an-
tibiotics is warranted. In one clinical trial, low lev-
els of procalcitonin (<0.1 μg per liter) were used 
to discriminate safely between patients with cough 
or dyspnea who did not require antibiotic therapy, 
such as those with acute bronchitis,38 and patients 
who did require such therapy. However, more data 
are needed to validate the usefulness of the pro-
calcitonin test for discriminating between patients 
with bronchitis and those with pneumonia.
Although clinicians might argue that the pres-
sure of time influences the prescribing of antibi-
otics, the data do not support this contention. 
A recent study involving almost 4000 adults with 
upper respiratory tract infections showed that the 
mean duration of an office visit was 14.2 minutes 
when antibiotics were prescribed, as compared 
with 15.2 minutes when no prescription for anti-
biotics was given.39
Previous studies involving volunteers exposed to 
rhinovirus showed that nonsteroidal drugs alone 
or in combination with antihistamines reduced the 
severity of symptoms, including cough.40 However, 
the effects of either drug alone or their combina-
tion in naturally occurring acute bronchitis have 
not been evaluated. Results of a single randomized 
trial involving 486 adults with acute bronchitis 
suggested a clinical benefit of an extract of the 
roots of Pelargonium sidoides, but the data require 
confirmation.41
Guidel ines
According to the 2001 guidelines of the Ameri-
can College of Physicians for the treatment of un-
complicated acute bronchitis, antibiotic treatment 
is “not recommended, regardless of duration of 
cough.” 42 According to the 2006 guidelines of 
the American College of Chest Physicians (ACCP) 
for treating acute bronchitis, routine treatment 
with antibiotics is not justified, antitussive agents 
are only occasionally useful, and there is no rou-
tine role for inhaled bronchodilators or muco-
lytic agents.43 However, these guidelines note that 
subgroups of patients with chronic airflow ob-
struction at baseline or wheezing at the onset of 
illness do have a benefit from β2-agonists. In-
haled anticholinergic agents are not recommended. 
These guidelines have been criticized on the 
grounds that many of the recommendations were 
based “more on opinion than on evidence.” 44
Both the ACCP guidelines and guidelines of the 
Centers for Disease Control and Prevention (CDC) 
recommend macrolides as first-line therapy for 
pertussis.25,43 For infection with influenza A virus, 
in January 2006 the CDC recommended therapy 
with either oseltamivir or zanamivir,21 noting that 
the circulating H3N2 strains of influenza A virus 
were almost uniformly resistant to both first-gen-
eration drugs (amantadine and rimantadine).
Summ a r y a nd R ecommendations
The patient described in the vignette most likely 
has a viral infection causing uncomplicated acute 
bronchitis. On the basis of data from clinical 
trials, antibacterial agents are not recommended. 
Chest radiography is not indicated, given the ab-
sence of signs of pneumonia on physical examina-
tion. In the absence of an influenza outbreak in 
the community, no rapid testing for viral causes 
should be ordered, and no antiviral therapy 
should be prescribed; influenza is especially un-
likely in a patient who is afebrile. In the absence 
of a history of contact with a person with sus-
pected pertussis (or a person with a history of 
persistent cough), this diagnosis is unlikely. If 
paroxysms of cough developed later or if whoop-
ing or post-tussive vomiting occurred, testing for 
pertussis would be reasonable. The patient should 
be advised that the cough may persist for an ad-
ditional 10 to 21 days and that infrequently, it 
persists longer. For his wheezing and shortness of 
breath with activity, clinical experience suggests 
that a β2-agonist such as albuterol may provide 
relief, although data from clinical trials are incon-
sistent. On the basis of clinical experience, the pa-
tient might be offered short-term use of codeine or 
hydrocodone-containing preparations or inhaled 
corticosteroids if the cough is persistent, although 
data from trials to support their use are lacking.
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